Every Form 4 that ClearPoint Neuro, Inc. (CLPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLPT filings page.
ClearPoint Neuro, Inc. (CLPT) CEO and President Joseph Burnett exercised 12,517 stock options on September 2, 2026 at an exercise price of $3.47 per share, paying the exercise price in cash. He received 12,517 shares of common stock and, according to the company disclosure, no shares were sold in connection with this transaction.
After the exercise, Burnett holds 130,720 shares of ClearPoint Neuro common stock directly and 191,388 shares indirectly through the Joseph M. Burnett Trust dated October 20, 2022, where he is trustee. The options exercised were part of a grant dated August 15, 2019 that vests over three years.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher received 662 shares of Common Stock as compensation. The shares were issued under the company’s incentive and non-employee director compensation plans at a value of $17.84 per share, matching the June 30, 2026 closing price. After this grant, Fletcher directly holds 131,011 shares.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Timothy T. Richards received 222 shares of Common Stock as compensation. The shares were granted on June 30, 2026 under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan.
The shares were valued at a price of $17.84 per share, matching the closing price of ClearPoint Neuro’s stock on June 30, 2026. Following this award, Richards directly holds 87,544 shares of ClearPoint Neuro common stock, indicating this was a routine, small incremental grant rather than a large new position.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall acquired 1,781 shares of common stock through the company’s Employee Stock Purchase Plan. These shares were purchased for $11.93 per share for the ESPP period from January 1, 2026 through June 30, 2026.
After this ESPP acquisition, Stigall directly holds a total of 110,263 shares of ClearPoint Neuro common stock. Under the ESPP terms, the purchase price was 85% of the fair market value on the first or last day of the purchase period, whichever was lower.
ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro acquired 1,085 shares of common stock through the company’s Employee Stock Purchase Plan. The shares relate to the ESPP purchase period from January 1, 2026 through June 30, 2026 and were bought at $11.93 per share. After this routine compensation-related acquisition, he directly holds 103,769 shares of ClearPoint Neuro common stock.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported routine insider activity involving company common stock. He acquired 1,361 shares of common stock on June 30, 2026 as a grant/award under the company’s Employee Stock Purchase Plan (ESPP) at $11.93 per share. The ESPP purchase covered the period from January 1, 2026 through June 30, 2026, with shares bought at 85% of the lower of the fair market value on the first or last day of that period. Following this ESPP acquisition, Burnett directly owns 118,203 shares of ClearPoint Neuro common stock and indirectly has 191,388 shares held through the Joseph M. Burnett Trust dated October 20, 2022, where he serves as trustee.
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock. He exercised stock options to acquire 20,000 shares at $2.50 per share and sold 20,000 shares in an open-market transaction at a weighted average price of $19.38 per share.
Following these transactions, he holds 116,842 shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. The filing notes the exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported an exercise-and-sell transaction in company stock. He exercised stock options for 60,000 shares of common stock at $2.50 per share and sold 60,000 shares held directly at a weighted average price of $17.79 per share. In a separate indirect transaction, the Joseph M. Burnett Trust dated 10/20/2022, for which he serves as trustee, sold 1,843 shares at a weighted average price of $17.94 per share. Following these transactions, Burnett held 116,842 shares directly and 191,388 shares indirectly through the trust, and the option award referenced in the filing covered 270,000 shares after the exercise. The filing notes that the option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
ClearPoint Neuro, Inc. director Timothy T. Richards exercised stock options and had shares withheld to cover taxes. He exercised options for 500 shares of Common Stock at $10.00 per share and 376 shares were disposed of at $13.30 per share for tax-withholding. Following these transactions, he directly owned 87,322 Common Stock shares, and the exercised option grant was fully used.
ClearPoint Neuro director Timothy T. Richards sold 5,415 shares of Common Stock. The open-market sale on June 1, 2026 was executed at a weighted average price of $12.17 per share, with individual trades ranging from $12.04 to $12.47 per share.
According to the filing, the sale was made to cover the tax liability associated with the vesting of 12,417 restricted stock units on May 19, 2026. After this transaction, Richards directly holds 87,198 shares of ClearPoint Neuro common stock.
FALLON LYNNETTE C reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Lynnette C. Fallon received a grant of 12,820 restricted stock units of common stock. Each unit represents a right to receive one CLPT share. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the company’s 2027 annual meeting.
LIAU LINDA M. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. director Linda M. Liau reported an equity award of restricted stock units. She received 12,820 restricted stock units, each representing a contingent right to receive one share of ClearPoint Neuro common stock. The units were granted at a price of $0.00 per unit.
The restricted stock units vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders. Following this grant, she directly holds 12,820 restricted stock units corresponding to 12,820 shares of common stock.
ClearPoint Neuro director Matthew B. Klein reported mixed equity activity. On May 21, 2026, he completed an open-market sale of 16,000 shares of common stock at a weighted average price of $11.59 per share and held 46,935 shares directly afterward. The sale prices ranged from $11.57 to $11.65.
On the same date, he received a grant of 12,820 restricted stock units (RSUs), each representing a contingent right to one share of ClearPoint Neuro common stock. These RSUs vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. director Timothy T. Richards received a grant of 12,820 restricted stock units. Each unit represents a right to receive one share of CLPT common stock and will vest on the earlier of the first anniversary of the grant date or the day immediately before the 2027 annual meeting of stockholders.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. director R John Fletcher received a grant of 12,820 restricted stock units as equity compensation. Each unit represents a contingent right to one share of CLPT common stock. The units vest on the earlier of the first anniversary of the grant date or the day immediately before the company’s 2027 annual meeting of stockholders. Following this award, Fletcher holds 12,820 RSUs directly.
JOHNSON B KRISTINE reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Kristine B. Johnson received a grant of restricted stock units. She was awarded 12,820 restricted stock units, each representing a contingent right to receive one share of ClearPoint Neuro common stock. These units vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders. After this award, she holds 12,820 RSUs directly related to ClearPoint Neuro common stock.
ClearPoint Neuro director Matthew B. Klein settled a restricted stock unit award into common shares. On the May 19, 2026 vesting date, 12,417 restricted stock units converted into an equal number of ClearPoint Neuro common shares at no cash exercise price. These RSUs were originally granted on May 22, 2025 and were scheduled to vest on the earlier of the first anniversary of the grant or the day immediately before the company’s 2026 annual stockholders’ meeting. Following this routine equity compensation event, Klein directly holds 62,935 shares of ClearPoint Neuro common stock.
ClearPoint Neuro director Lynnette C. Fallon reported routine equity compensation activity. She exercised 12,417 restricted stock units into common stock at a conversion price of $0.00 per share, then sold 5,091 shares at a weighted average price of $11.14.
The footnotes state the sale was made under a pre-arranged Rule 10b5-1 trading plan to cover tax liabilities from the RSU vesting, rather than a discretionary trade. After these transactions, she directly holds 48,227 shares of ClearPoint Neuro common stock.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher increased his direct holdings through routine equity compensation. On May 19, 2026, 12,417 restricted stock units vested and were settled into 12,417 shares of common stock, with no open-market buying or selling involved.
These RSUs were originally granted on May 22, 2025 and vested on their scheduled date, tied to the first anniversary or the day before the 2026 annual stockholder meeting. Following the settlement, Fletcher directly holds 130,349 shares of ClearPoint Neuro common stock.
ClearPoint Neuro director Timothy T. Richards exercised 12,417 restricted stock units into 12,417 shares of common stock. The RSUs were granted on May 22, 2025 and vested on their scheduled vesting date, converting into common shares at no cash exercise price.
Following this settlement of equity compensation, Richards directly owns 92,613 shares of ClearPoint Neuro common stock. The filing does not show any open-market purchases or sales, only the vesting and share issuance related to previously granted RSUs.
ClearPoint Neuro director Kristine B. Johnson exercised and settled 12,417 restricted stock units into an equal number of common shares on May 19, 2026. These RSUs were granted on May 22, 2025 and vested on their scheduled vesting date. After the settlement, she directly holds 71,116 shares of ClearPoint Neuro common stock.
ClearPoint Neuro director Pascal E. R. Girin settled a restricted stock unit award into common shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro, Inc. common stock at no cash exercise price. After this settlement, he directly holds 110,623 common shares. The RSUs were originally granted on May 22, 2025 and vested on their scheduled vesting date tied to the earlier of the first anniversary of grant or the day before the company’s 2026 annual meeting of stockholders.
ClearPoint Neuro director Linda M. Liau acquired 12,417 shares of common stock through settlement of restricted stock units. These RSUs were granted on May 22, 2025 and vested on their scheduled date, converting into the same number of common shares. After this compensation-related transaction, she holds 64,801 shares of ClearPoint Neuro common stock directly. No open-market buys or sells were reported in this filing.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher received 1,270 shares of common stock as a grant. The shares were issued at $9.10 per share under the company’s incentive compensation plan as payment of fees owed under the Non-Employee Director Compensation Plan.
Following this compensation-related issuance, Fletcher directly holds 117,932 shares of ClearPoint Neuro common stock.
Girin Pascal E R reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Pascal E. R. Girin received 755 shares of Common Stock as compensation. The shares were granted at $9.10 per share under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan. Following this award, Girin directly holds 98,206 shares of ClearPoint Neuro common stock.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Timothy T. Richards received 442 shares of Common Stock as compensation, valued at $9.10 per share. The award was issued under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan in payment of fees owed under the Non-Employee Director Compensation Plan.
Following this grant, Richards directly holds 80,196 shares of ClearPoint Neuro common stock. The shares were issued at the closing price of the company’s common stock on March 31, 2026, making this a routine, stock-settled director fee payment rather than an open-market purchase.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett exercised stock options to acquire 20,942 shares of Common Stock at $3.24 per share. He paid the exercise price in cash and no shares were sold; all shares received were retained.
Following the exercise, Burnett directly owns 116,842 shares of Common Stock. In addition, 193,231 shares are held indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro settled 32,627 restricted stock units into an equal number of shares of common stock on their scheduled vesting date.
Of these, 16,601 shares were delivered back to ClearPoint Neuro at $11.53 per share to cover tax withholding, leaving him with 102,684 shares of common stock held directly.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett settled 84,829 restricted stock units, receiving the same number of common shares upon vesting. To cover tax withholding obligations, 43,161 common shares were delivered back to ClearPoint Neuro at $11.53 per share, which is not an open-market sale. Following these transactions, Burnett holds 95,900 common shares directly and an additional 193,231 common shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares as part of scheduled vesting. Each unit converts into one share of common stock, and this transaction reflects the routine exercise or conversion of 30,995 restricted stock units.
In connection with the vesting, 15,151 shares of common stock were delivered back to ClearPoint Neuro at $11.53 per share to satisfy tax withholding obligations, rather than being sold in the open market. After these transactions, Stigall directly holds 108,482 shares of common stock.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin exercised and settled 26,101 restricted stock units into the same number of shares of common stock on their scheduled vesting date. Each unit represented a right to receive one share of common stock.
To cover tax withholding obligations tied to this vesting, 13,281 common shares were delivered back to ClearPoint Neuro at 11.5300 per share, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly holds 67,343 shares of common stock.
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity involving restricted stock units. On March 11, 2026, 4,145 restricted stock units settled into the same number of common shares at a stated price of $0.00 per share, reflecting non-cash vesting.
In connection with this vesting, 2,109 common shares were delivered back to ClearPoint Neuro at $11.62 per share to satisfy tax withholding obligations, not as an open-market sale. After these transactions, D’Alessandro directly held 86,658 shares of common stock.
ClearPoint Neuro Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares. He exercised 8,291 restricted stock units into 8,291 shares of common stock. Of these, 3,224 shares at $11.62 per share were delivered back to ClearPoint Neuro to cover tax withholding, leaving him with 92,638 common shares held directly after the transactions.
ClearPoint Neuro CEO Joseph Burnett reported routine equity compensation activity. On March 6, 2026, 47,407 restricted stock units converted into the same number of shares of common stock at a stated price of $0.00 per share, reflecting scheduled vesting.
To cover tax obligations from this vesting, 22,709 common shares were delivered back to ClearPoint Neuro at $10.00 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Burnett directly holds 54,232 common shares and indirectly holds 193,231 common shares through the Joseph M. Burnett Trust dated October 20, 2022.
ClearPoint Neuro Chief Business Officer Jeremy L. Stigall settled previously granted equity awards into common shares and had part withheld for taxes. On 2026-03-06, he exercised 17,778 restricted stock units, receiving the same number of ClearPoint Neuro common shares at an exercise price of $0.00 per share.
To cover tax obligations tied to this vesting, 6,913 common shares were delivered back to ClearPoint Neuro at $10.00 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Stigall directly owned 87,571 common shares of ClearPoint Neuro.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin settled previously granted restricted stock units into 13,827 shares of common stock on their scheduled vesting date. To cover tax withholding obligations, 7,036 shares were delivered back to ClearPoint Neuro. Following these compensation-related transactions, Mazin directly holds 54,523 shares of common stock.
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity. He exercised 18,765 restricted stock units, converting them into the same number of common shares at a stated price of $0.00 per share as part of a scheduled vesting.
To cover tax obligations from this vesting, 9,548 common shares were delivered back to ClearPoint Neuro at $10.00 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, D’Alessandro directly holds 84,622 common shares of ClearPoint Neuro.
ClearPoint Neuro, Inc. director and CEO Joseph Burnett settled restricted stock units into common shares on March 3, 2026. He acquired 26,568 shares of common stock upon vesting of restricted stock units, each representing one share of common stock.
To cover tax withholding obligations tied to this vesting, 9,533 common shares were delivered to ClearPoint Neuro at $8.84 per share. Following these transactions, Burnett held 29,534 shares of common stock directly and 193,231 shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022.
ClearPoint Neuro, Inc. Chief Financial Officer Danilo D'Alessandro reported equity award activity. On March 3, 2026, he exercised 10,332 Restricted Stock Units, converting them into 10,332 shares of common stock, as part of a scheduled vesting. Following this, his directly held common stock position was 75,405 shares, and his remaining directly held Restricted Stock Units totaled 41,328 units. To cover tax withholding tied to the vesting, 5,257 shares of common stock were delivered to ClearPoint Neuro at a price of $8.84 per share in a tax-withholding disposition.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall reported vesting of 8,856 restricted stock units, which were settled into an equal number of shares of common stock at a stated price of $0.0000 per share on March 3, 2026.
In connection with this vesting, 4,506 shares of common stock were delivered to ClearPoint Neuro at $8.84 per share to cover tax withholding obligations. Following these transactions, Stigall held 35,424 restricted stock units and 76,706 shares of common stock, all reported as directly owned.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin reported equity award activity involving restricted stock units and common stock. On March 3, 2026, 6,642 restricted stock units were settled into the same number of shares of common stock at $0.00 per share, reflecting a scheduled vesting. In connection with this vesting, 3,380 common shares were delivered back to ClearPoint Neuro at $8.84 per share to satisfy tax withholding obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly held 47,732 shares of common stock and 26,568 restricted stock units.
ClearPoint Neuro CEO-related trust reports planned share sale
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported that a trust for which he serves as trustee sold 19,951 shares of common stock on February 25, 2026 in an open-market transaction at a weighted-average price of $15.17 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025. After the sale, the trust-related indirect holding stood at 193,231 shares, while Burnett’s direct ownership was 12,499 shares, reflecting a prior transfer of 934 shares from the trust on February 6, 2026.
ClearPoint Neuro, Inc. reported that Chief Operating Officer Sabra Mazin acquired 36,818 restricted stock units (RSUs) of company stock as a compensation award. Each RSU represents a contingent right to receive one share of CLPT common stock if vesting conditions are met.
The award vests over three years: 20% of the RSUs on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029. After this grant, Mazin directly holds 36,818 RSUs, aligning part of her compensation with the company’s future performance.
STIGALL L. JEREMY reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall received a grant of 51,546 restricted stock units of ClearPoint Neuro common stock. Each unit represents the right to receive one share of CLPT common stock at vesting. The award vests over three years: 20% of the units on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning a substantial portion of his compensation with the company’s long-term performance.
D'Alessandro Danilo reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. reported that Chief Financial Officer Danilo D'Alessandro received a grant of 66,273 restricted stock units. Each unit represents a contingent right to one share of CLPT common stock. The units vest 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029.
ClearPoint Neuro, Inc. reported that CEO and President Joseph Burnett acquired a grant of 147,275 restricted stock units. Each unit represents a contingent right to receive one share of CLPT common stock.
The restricted stock units vest over three years: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning the award with multi-year executive retention and performance incentives.
ClearPoint Neuro, Inc. insider activity: a trust associated with CEO and President Joseph Burnett sold 2,943 shares of ClearPoint Neuro common stock on 01/26/2026 at a weighted average price of $15.57 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
After this sale, the Joseph M. Burnett Trust held 214,116 shares indirectly for Mr. Burnett, and he also held 11,565 shares directly. The sale price range was from $15.23 to $15.65 per share, and detailed trade breakdowns are available from the company or the SEC staff upon request.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported option exercises and a stock sale. On 01/09/2026 he exercised 20,000 stock options with a $2.50 exercise price, receiving 20,000 shares of common stock, and on the same day sold 20,000 common shares at a weighted average price of $16.12 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, he directly holds 11,565 common shares and 330,000 stock options, and indirectly holds 217,059 common shares through the Joseph M. Burnett Trust dated 10/20/2022.
ClearPoint Neuro, Inc. (CLPT) reported an insider equity transaction by its Chief Financial Officer, Danilo D'Alessandro. On 11/21/2025, he exercised stock options to acquire 3,555 shares of common stock at an exercise price of $8.10 per share and held all shares received, with no stock sold in connection with the transaction. Following this exercise, he beneficially owns 69,923 shares of ClearPoint Neuro common stock in direct ownership form.
The exercised options were part of a grant dated March 6, 2023, with vesting in three tranches: 20% on the first anniversary, 40% on the second, and 40% on the third. After the reported transaction, 12,082 stock options remain beneficially owned, with an expiration date of 03/06/2033.
ClearPoint Neuro (CLPT) CEO and President Joseph M. Burnett, also a Director, reported open‑market sales of Common Stock on 10/10/2025 under a Rule 10b5‑1 trading plan adopted on June 11, 2025.
Transactions disclosed: 17,583 shares at a weighted average price of $26.51 (range $26.07–$27.06); 6,599 shares at $27.64 (range $27.08–$28.07); 1,981 shares at $28.64 (range $28.08–$29.05); and 300 shares at $29.21.
Following these transactions, 217,059 shares were beneficially owned indirectly by the Joseph M. Burnett Trust (with Mr. Burnett as trustee), and 11,311 shares were owned directly.